Tim G J de Meij1, Nanne K H de Boer2, Marc A Benninga3, Yvette E Lentferink4, Evelien F J de Groot4, Mirjam E van de Velde4, Adriaan A van Bodegraven2, Marc P van der Schee5. 1. Department of Pediatric Gastroenterology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Electronic address: t.demeij@vumc.nl. 2. Department of Gastroenterology and Hepatology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. 3. Department of Pediatric Gastroenterology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 4. Department of Pediatric Gastroenterology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. 5. Department of Pulmonology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Abstract
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) and its two phenotypes ulcerative colitis (UC) and Crohn's disease (CD) are essentially assessed by endoscopy, both in initial diagnostic work-up and during follow-up. This carries a high burden, especially on paediatric patients. Faecal volatile organic compounds (VOCs) are considered potential non-invasive biomarkers for intestinal diseases linked to gut microbiota alterations. We hypothesized that faecal VOC analysis by electronic nose allows discrimination of children with CD, UC and controls during active disease and remission. METHODS: Faecal VOC patterns of children with newly diagnosed IBD and controls were studied by an electronic nose (Cyranose 320®), at baseline and upon achieving remission at 6-weeks of follow-up. Disease activity was assessed by global physician's assessment, substantiated by serum C-reactive protein and faecal calprotectin. Internally cross-validated receiver-operator-characteristic curves and corresponding sensitivity and specificity for detection of IBD were calculated RESULTS: Faecal VOC profiles of patients with UC (26) and CD (29) differed from controls (28); in active disease (AUC±95% CI, p-value, sensitivity, specificity: 1.00±0.00; p<0.001, 100%, 100%) and (0.85±0.05, p<0.001, 86%, 67%) and in clinical remission (0.94±0.06, p<0.001, 94%, 94%) and (0.94±0.06, p<0.001, 94%, 94%), respectively. Furthermore, CD-patients differed from UC-patients during active disease (0.96±0.03; p<0.001, 97%, 92%), and upon achieving clinical remission (0.81±0.08, p=0.002, 88%, 72%). CONCLUSION: Faecal VOC analysis allowed discrimination of paediatric patients with IBD from controls, both during active disease and remission. It therefore has potential as non-invasive test, in both diagnostic work-up and assessment of disease activity in IBD.
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) and its two phenotypes ulcerative colitis (UC) and Crohn's disease (CD) are essentially assessed by endoscopy, both in initial diagnostic work-up and during follow-up. This carries a high burden, especially on paediatric patients. Faecal volatile organic compounds (VOCs) are considered potential non-invasive biomarkers for intestinal diseases linked to gut microbiota alterations. We hypothesized that faecal VOC analysis by electronic nose allows discrimination of children with CD, UC and controls during active disease and remission. METHODS: Faecal VOC patterns of children with newly diagnosed IBD and controls were studied by an electronic nose (Cyranose 320®), at baseline and upon achieving remission at 6-weeks of follow-up. Disease activity was assessed by global physician's assessment, substantiated by serum C-reactive protein and faecal calprotectin. Internally cross-validated receiver-operator-characteristic curves and corresponding sensitivity and specificity for detection of IBD were calculated RESULTS: Faecal VOC profiles of patients with UC (26) and CD (29) differed from controls (28); in active disease (AUC±95% CI, p-value, sensitivity, specificity: 1.00±0.00; p<0.001, 100%, 100%) and (0.85±0.05, p<0.001, 86%, 67%) and in clinical remission (0.94±0.06, p<0.001, 94%, 94%) and (0.94±0.06, p<0.001, 94%, 94%), respectively. Furthermore, CD-patients differed from UC-patients during active disease (0.96±0.03; p<0.001, 97%, 92%), and upon achieving clinical remission (0.81±0.08, p=0.002, 88%, 72%). CONCLUSION: Faecal VOC analysis allowed discrimination of paediatric patients with IBD from controls, both during active disease and remission. It therefore has potential as non-invasive test, in both diagnostic work-up and assessment of disease activity in IBD.
Authors: Brian D Hosfield; Anthony R Pecoraro; Nielson T Baxter; Troy B Hawkins; Troy A Markel Journal: J Surg Res Date: 2020-06-08 Impact factor: 2.192
Authors: Daniel J C Berkhout; Hendrik J Niemarkt; Marc A Benninga; Andries E Budding; Anton H van Kaam; Boris W Kramer; Charlene M Pantophlet; Mirjam M van Weissenbruch; Nanne K H de Boer; Tim G J de Meij Journal: Pediatr Res Date: 2017-11-22 Impact factor: 3.756
Authors: Evelien F de Groot; Tim G de Meij; Daniel J Berkhout; Marc P van der Schee; Nanne K de Boer Journal: World J Gastrointest Pharmacol Ther Date: 2015-11-06
Authors: Brian D Hosfield; Natalie A Drucker; Anthony R Pecoraro; William C Shelley; Hongge Li; Nielson T Baxter; Troy B Hawkins; Troy A Markel Journal: J Pediatr Surg Date: 2021-02-24 Impact factor: 2.549
Authors: Daniel J C Berkhout; Marc A Benninga; Ruby M van Stein; Paul Brinkman; Hendrik J Niemarkt; Nanne K H de Boer; Tim G J de Meij Journal: Sensors (Basel) Date: 2016-11-23 Impact factor: 3.576
Authors: Lorenzo Monasta; Chiara Pierobon; Andrea Princivalle; Stefano Martelossi; Annalisa Marcuzzi; Francesco Pasini; Luigi Perbellini Journal: PLoS One Date: 2017-08-31 Impact factor: 3.240
Authors: Sofia El Manouni El Hassani; Hendrik J Niemarkt; Hager Said; Daniel J C Berkhout; Anton H van Kaam; Richard A van Lingen; Marc A Benninga; Nanne K H de Boer; Tim G J de Meij Journal: Sensors (Basel) Date: 2018-09-11 Impact factor: 3.576